

Paolo Paganetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8089212/publications.pdf>

Version: 2024-02-01

77
papers

15,478
citations

81743

39
h-index

66788

78
g-index

87
all docs

87
docs citations

87
times ranked

27482
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	4.3	4,701
2	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	4.3	3,122
3	Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 13287-13292.	3.3	1,355
4	Exogenous Induction of Cerebral β -Amyloidogenesis Is Governed by Agent and Host. <i>Science</i> , 2006, 313, 1781-1784.	6.0	875
5	Role of EDEM in the Release of Misfolded Glycoproteins from the Calnexin Cycle. <i>Science</i> , 2003, 299, 1397-1400.	6.0	431
6	Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation. <i>Cell</i> , 2009, 137, 60-72.	13.5	367
7	Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease. <i>Journal of Biological Chemistry</i> , 2010, 285, 8808-8823.	1.6	259
8	Amyloid β interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. <i>Nature Neuroscience</i> , 2000, 3, 460-464.	7.1	252
9	Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. <i>Nature Communications</i> , 2017, 8, 45.	5.8	242
10	Membrane-type 1 Matrix Metalloprotease (MT1-MMP) Enables Invasive Migration of Glioma Cells in Central Nervous System White Matter. <i>Journal of Cell Biology</i> , 1999, 144, 373-384.	2.3	232
11	Sequential assistance of molecular chaperones and transient formation of covalent complexes during protein degradation from the ER. <i>Journal of Cell Biology</i> , 2002, 158, 247-257.	2.3	204
12	Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. <i>Human Molecular Genetics</i> , 2010, 19, 65-78.	1.4	185
13	EDEM1 regulates ER-associated degradation by accelerating de-mannosylation of folding-defective polypeptides and by inhibiting their covalent aggregation. <i>Biochemical and Biophysical Research Communications</i> , 2006, 349, 1278-1284.	1.0	154
14	The Carboxyl Termini of β -Amyloid Peptides 1-40 and 1-42 Are Generated by Distinct β -Secretase Activities. <i>Journal of Biological Chemistry</i> , 1996, 271, 28655-28659.	1.6	151
15	Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. <i>Journal of Clinical Investigation</i> , 2011, 121, 3306-3319.	3.9	151
16	ER-associated degradation of proteasome-resistant ATZ polymers occurs via receptor-mediated vesicular transport. <i>EMBO Journal</i> , 2018, 37, .	3.5	144
17	Expression of human beta-secretase in the mouse brain increases the steady-state level of beta-amyloid. <i>Journal of Neurochemistry</i> , 2002, 80, 799-806.	2.1	116
18	Single-step detection of mutant huntingtin in animal and human tissues: A bioassay for Huntington's disease. <i>Analytical Biochemistry</i> , 2009, 395, 8-15.	1.1	115

#	ARTICLE	IF	CITATIONS
19	Targeting Presenilin-type Aspartic Protease Signal Peptide Peptidase with $\hat{\Gamma}^3$ -Secretase Inhibitors. <i>Journal of Biological Chemistry</i> , 2003, 278, 16528-16533.	1.6	114
20	BACE ($\hat{\Gamma}^2$ -secretase) modulates the processing of APLP2 in vivo. <i>Molecular and Cellular Neurosciences</i> , 2004, 25, 642-649.	1.0	107
21	Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. <i>Journal of Neurochemistry</i> , 2008, 104, 846-858.	2.1	103
22	Suppression of protein aggregation by chaperone modification of high molecular weight complexes. <i>Brain</i> , 2012, 135, 1180-1196.	3.7	103
23	Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. <i>Human Molecular Genetics</i> , 2010, 19, 1528-1538.	1.4	100
24	$\hat{\Gamma}^2$ -site specific intrabodies to decrease and prevent generation of Alzheimer's A $\hat{\Gamma}^2$ peptide. <i>Journal of Cell Biology</i> , 2005, 168, 863-868.	2.3	98
25	Hdac6 Knock-Out Increases Tubulin Acetylation but Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease. <i>PLoS ONE</i> , 2011, 6, e20696.	1.1	91
26	Intracellular Accumulation of $\hat{\Gamma}^2$ -Amyloid in Cells Expressing the Swedish Mutant Amyloid Precursor Protein. <i>Journal of Biological Chemistry</i> , 1995, 270, 26727-26730.	1.6	88
27	The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease. <i>Molecular Neurodegeneration</i> , 2010, 5, 26.	4.4	86
28	Induction of autophagy with catalytic mTOR inhibitors reduces huntingtin aggregates in a neuronal cell model. <i>Journal of Neurochemistry</i> , 2011, 119, 398-407.	2.1	85
29	A Screen for Enhancers of Clearance Identifies Huntingtin as a Heat Shock Protein 90 (Hsp90) Client Protein. <i>Journal of Biological Chemistry</i> , 2012, 287, 1406-1414.	1.6	84
30	Effect of alkalizing agents on the processing of the $\hat{\Gamma}^2$ -amyloid precursor protein. <i>Brain Research</i> , 1996, 716, 91-100.	1.1	77
31	A Splice Variant of $\hat{\Gamma}^2$ -Secretase Deficient in the Amyloidogenic Processing of the Amyloid Precursor Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 12019-12023.	1.6	74
32	Structure-Based Design, Synthesis, and Memapsin 2 (BACE) Inhibitory Activity of Carbocyclic and Heterocyclic Peptidomimetics. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 5175-5190.	2.9	74
33	TR-FRET-Based Duplex Immunoassay Reveals an Inverse Correlation of Soluble and Aggregated Mutant huntingtin in Huntington's Disease. <i>Chemistry and Biology</i> , 2012, 19, 264-275.	6.2	70
34	Detection of a Soluble Form of BACE-1 in Human Cerebrospinal Fluid by a Sensitive Activity Assay. <i>Clinical Chemistry</i> , 2006, 52, 1168-1174.	1.5	66
35	Macrocyclic BACE-1 inhibitors acutely reduce A $\hat{\Gamma}^2$ in brain after po application. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 603-607.	1.0	55
36	Macrocyclic peptidomimetic $\hat{\Gamma}^2$ -secretase (BACE-1) inhibitors with activity in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1366-1370.	1.0	54

#	ARTICLE	IF	CITATIONS
37	Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic β -Amyloid-42 Fibril Formation. <i>Journal of Biological Chemistry</i> , 2012, 287, 34786-34800.	1.6	53
38	BACE-1 is expressed in the blood-brain barrier endothelium and is upregulated in a murine model of Alzheimer's disease. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 1281-1294.	2.4	53
39	EDEM Contributes to Maintenance of Protein Folding Efficiency and Secretory Capacity. <i>Journal of Biological Chemistry</i> , 2004, 279, 44600-44605.	1.6	40
40	Tau affects P53 function and cell fate during the DNA damage response. <i>Communications Biology</i> , 2020, 3, 245.	2.0	36
41	Structure-based design and synthesis of macrocyclic peptidomimetic β -secretase (BACE-1) inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 1361-1365.	1.0	35
42	Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects. <i>Scientific Reports</i> , 2017, 7, 13556.	1.6	35
43	The disulphide bonds in the catalytic domain of BACE are critical but not essential for amyloid precursor protein processing activity. <i>Journal of Neurochemistry</i> , 2002, 80, 1079-1088.	2.1	31
44	Split GFP technologies to structurally characterize and quantify functional biomolecular interactions of FTD-related proteins. <i>Scientific Reports</i> , 2017, 7, 14013.	1.6	31
45	Phosphorylation of nuclear Tau is modulated by distinct cellular pathways. <i>Scientific Reports</i> , 2018, 8, 17702.	1.6	31
46	Atg4b-Dependent Autophagic Flux Alleviates Huntington's Disease Progression. <i>PLoS ONE</i> , 2013, 8, e68357.	1.1	30
47	Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction. <i>Molecular Neurodegeneration</i> , 2009, 4, 11.	4.4	29
48	Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer. <i>Brain Sciences</i> , 2020, 10, 862.	1.1	28
49	LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington's Disease. <i>Journal of Huntington's Disease</i> , 2016, 5, 347-355.	0.9	27
50	HSF1-dependent and -independent regulation of the mammalian in vivo heat shock response and its impairment in Huntington's disease mouse models. <i>Scientific Reports</i> , 2017, 7, 12556.	1.6	27
51	Perturbation with Intrabodies Reveals That Calpain Cleavage Is Required for Degradation of Huntingtin Exon 1. <i>PLoS ONE</i> , 2011, 6, e16676.	1.1	27
52	Consequences of Individual N-glycan Deletions and of Proteasomal Inhibition on Secretion of Active BACE. <i>Molecular Biology of the Cell</i> , 2008, 19, 4086-4098.	0.9	25
53	Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. <i>PLOS Currents</i> , 2010, 2, RRN1205.	1.4	24
54	β -Secretase cleavage is not required for generation of the intracellular C-terminal domain of the amyloid precursor family of proteins. <i>FEBS Journal</i> , 2010, 277, 1503-1518.	2.2	22

#	ARTICLE	IF	CITATIONS
55	Hijacking Endocytosis and Autophagy in Extracellular Vesicle Communication: Where the Inside Meets the Outside. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 595515.	1.8	22
56	Development of a Method for the High-Throughput Quantification of Cellular Proteins. <i>ChemBioChem</i> , 2009, 10, 1678-1688.	1.3	21
57	Yeast growth selection system for the identification of cell-active inhibitors of β -secretase. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2004, 1674, 29-39.	1.1	20
58	Human genome-guided identification of memory-modulating drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, E4369-74.	3.3	20
59	Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats. <i>Experimental Neurology</i> , 2016, 280, 80-88.	2.0	20
60	BACE1 and Mutated Presenilin-1 Differently Modulate $A\beta_{40}$ and $A\beta_{42}$ Levels and Cerebral Amyloidosis in APP Dutch Transgenic Mice. <i>Neurodegenerative Diseases</i> , 2007, 4, 127-135.	0.8	19
61	Distinct Processing of Endogenous and Overexpressed Recombinant Presenilin 1. <i>Neurobiology of Aging</i> , 1997, 18, 181-189.	1.5	18
62	Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence. <i>Journal of Neuro-Oncology</i> , 2017, 133, 497-507.	1.4	18
63	Huntingtin cleavage product A forms in neurons and is reduced by gamma-secretase inhibitors. <i>Molecular Neurodegeneration</i> , 2010, 5, 58.	4.4	16
64	Heterogeneous distribution of calmodulin-and cAMP-dependent regulation of Ca^{2+} uptake in cardiac sarcoplasmic reticulum subfractons. <i>FEBS Journal</i> , 1988, 176, 535-541.	0.2	15
65	Protoporphyrin IX tracer fluorescence modulation for improved brain tumor cell lines visualization. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2019, 201, 111640.	1.7	15
66	Rapid Cerebral Amyloid Binding by $A\beta$ Antibodies Infused into $A\beta$ -Amyloid Precursor Protein Transgenic Mice. <i>Biological Psychiatry</i> , 2010, 68, 971-974.	0.7	14
67	Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. <i>Analytical Biochemistry</i> , 2011, 410, 304-306.	1.1	14
68	Synthesis and structure-activity relationship of 2,6-disubstituted pyridine derivatives as inhibitors of $A\beta_{42}$ aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3330-3335.	1.0	14
69	Proteolytic processing of the Aplysia A peptide precursor in AtT-20 cells. <i>Brain Research</i> , 1994, 633, 53-62.	1.1	13
70	Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse. <i>Behavioural Brain Research</i> , 2012, 229, 308-319.	1.2	11
71	Increased Efflux of Amyloid- β Peptides through the Blood-Brain Barrier by Muscarinic Acetylcholine Receptor Inhibition Reduces Pathological Phenotypes in Mouse Models of Brain Amyloidosis. <i>Journal of Alzheimer's Disease</i> , 2013, 38, 767-786.	1.2	11
72	The heat shock response, determined by QuantiGene multiplex, is impaired in HD mouse models and not caused by HSF1 reduction. <i>Scientific Reports</i> , 2021, 11, 9117.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Transgenic expression of $\hat{2}1$ antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice. <i>Neurobiology of Aging</i> , 2013, 34, 2866-2878.	1.5	4
74	Tau Seeds in Extracellular Vesicles Induce Tau Accumulation in Degradative Organelles of Cells. <i>DNA and Cell Biology</i> , 2021, 40, 1185-1199.	0.9	3
75	Splicing of intron 3 of human BACE requires the flanking introns 2 and 4. <i>Biochemical and Biophysical Research Communications</i> , 2009, 388, 434-438.	1.0	2
76	Chloroquine, the Coronavirus Crisis, and Neurodegeneration: A Perspective. <i>Frontiers in Neurology</i> , 2020, 11, 596528.	1.1	2
77	Deciphering the role of tau in neurodegeneration using Adeno-Associated Viral (AAV) vectors to express human tau in the mouse forebrain. <i>Molecular Neurodegeneration</i> , 2013, 8, .	4.4	0